Free Trial

DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

DiaMedica Therapeutics logo
$3.63 -0.04 (-1.09%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.76 +0.14 (+3.72%)
As of 07/11/2025 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DiaMedica Therapeutics Stock (NASDAQ:DMAC)

Key Stats

Today's Range
$3.58
$3.70
50-Day Range
$3.51
$4.27
52-Week Range
$3.11
$6.82
Volume
82,747 shs
Average Volume
102,009 shs
Market Capitalization
$155.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

DiaMedica Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

DMAC MarketRank™: 

DiaMedica Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 883rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about DiaMedica Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DiaMedica Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DiaMedica Therapeutics is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DiaMedica Therapeutics has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DiaMedica Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.33% of the float of DiaMedica Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently increased by 72.36%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    DiaMedica Therapeutics does not currently pay a dividend.

  • Dividend Growth

    DiaMedica Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.33% of the float of DiaMedica Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    DiaMedica Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in DiaMedica Therapeutics has recently increased by 72.36%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    DiaMedica Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for DiaMedica Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for DMAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.30% of the stock of DiaMedica Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 10.12% of the stock of DiaMedica Therapeutics is held by institutions.

  • Read more about DiaMedica Therapeutics' insider trading history.
Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMAC Stock News Headlines

DiaMedica Therapeutics Inc. (DMAC) - Yahoo Finance
DMAC DiaMedica Therapeutics Inc. - Seeking Alpha
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

DMAC Stock Analysis - Frequently Asked Questions

DiaMedica Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, DMAC shares have decreased by 33.1% and is now trading at $3.63.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18).
Read the conference call transcript
.

DiaMedica Therapeutics (DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NVIDIA (NVDA), ADMA Biologics (ADMA), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/13/2025
Today
7/12/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DMAC
CIK
1401040
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+120.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-61.35%
Return on Assets
-55.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.02
Quick Ratio
8.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.95 per share
Price / Book
3.82

Miscellaneous

Outstanding Shares
42,880,000
Free Float
39,753,000
Market Cap
$155.65 million
Optionable
Optionable
Beta
1.17
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:DMAC) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners